Table 2.
Correlation of p16/p53/MDM2 immunoprofile in ESCC patients with p16 methylation and clinicopathological features
| Alteration | |||||
|---|---|---|---|---|---|
| a | b | c | d | p value | |
| p16 methylation | |||||
| Positive | 3 (33.3) | 6 (46.2) | 12 (70.6) | 10 (90.9) | 0.028 |
| Negative | 6 (66.7) | 7 (53.8) | 5 (29.4) | 1 (9.1) | |
| Tobacco use | |||||
| Positive | 2 (22.2) | 7 (58.3) | 3 (21.4) | 2 (18.2) | 0.145 |
| Negative | 7 (77.8) | 5 (41.7) | 11 (78.6) | 9 (81.8) | |
| Histology | |||||
| Well | 3 (33.3) | 7(53.8) | 6 (50) | 9 (81.8) | 0.173 |
| Moderate | 2 (22.2) | 4 (30.8) | 5 (41.7) | 2 (18.2) | |
| Poor | 4 (44.4) | 2 (15.4) | 1 (8.3) | 0 (0.0) | |
| Tissue | |||||
| Tumor | 9 (56.2) | 13 (43.4) | 17 (80.9) | 11 (100) | 0.001 |
| Normal | 7 (43.8) | 17 (56.6) | 4 (19.1) | 0 (0.0) | |
a p16+/p53-/MDM2- profile
bp16-/p53-/MDM2- profile or p16+/p53+/MDM2- profile or p16+/p53-/MDM2+ profile
cp16-/p53+/MDM2- profile or p16-/p53-/MDM2+ profile or p16+/p53+/MDM2+ profile
dp16-/p53+/MDM2+ profile